产品名称

AT 1001

产品货号

Axon 2401 CAS [1314801-63-2] MF C15H21BrN2MW 309.24 Purity: 100% Optical purity: Relative stereochemistry Soluble in 0.1N HCl(aq) and DMSO Description High affinity and selective α3β4 nAChR ligand (Ki value 2.6 nM at α3β4 nAChR) with both partial agonistic and antagonistic effects, and >90-fold selective over the other major subtypes, the α4β2 and α7 nAChR. AT-1001 potently and dose-dependently blocks nicotine self-administration in rats, without affecting food responding, and shows a mechanism of action very different from varenicline (Axon 1384 (HCl salt) and Axon 2074 (tartrate salt)). References Certificates Categories Extra info A. Cippitelli et al. AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45. L. Toll et al. AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology. 2012 May;37(6):1367-76. E.W. Tuan et al. AT-1001 is a Partial Agonist with High Affinity and Selectivity at Human and Rat α3β4 Nicotinic Cholinergic Receptors. Mol Pharmacol. 2015 Jul 10. pii: mol.115.099978. [Epub ahead of print] Certificate of Analysis Material Safety Data Sheet CNS Pain & Inflammation nAChR Unclassified High affinity and selective α3β4 nAChR ligand with partial agonistic and antagonistic effects Chemical name N-(2-bromophenyl)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine Parent CAS No. [1314801-63-2] Order Size Unit Price Stock 10 mg €95.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

AT 1001

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 2401

CAS [1314801-63-2]

MF C15H21BrN2
MW 309.24

Purity: 100%
Optical purity: Relative stereochemistry
Soluble in 0.1N HCl(aq) and DMSO

AT 1001

Description

High affinity and selective α3β4 nAChR ligand (Ki value 2.6 nM at α3β4 nAChR) with both partial agonistic and antagonistic effects, and >90-fold selective over the other major subtypes, the α4β2 and α7 nAChR. AT-1001 potently and dose-dependently blocks nicotine self-administration in rats, without affecting food responding, and shows a mechanism of action very different from varenicline (Axon 1384 (HCl salt) and Axon 2074 (tartrate salt)).